Latest Insider Transactions at Adaptimmune Therapeutics PLC (ADAP)
This section provides a real-time view of insider transactions for Adaptimmune Therapeutics PLC (ADAP). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Adaptimmune Therapeutics PLC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Adaptimmune Therapeutics PLC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 12
2022
|
Adrian Rawcliffe Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,046
-47.58%
|
$9,138
$3.54 P/Share
|
|
Jan 12
2022
|
Elliot Norry Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
854
-38.18%
|
$2,562
$3.54 P/Share
|
|
Jan 12
2022
|
John Lunger Chief Patient Supply Officer |
SELL
Open market or private sale
|
Direct |
1,076
-38.09%
|
$3,228
$3.54 P/Share
|
|
Jan 12
2022
|
William C Bertrand Jr Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,248
-37.45%
|
$6,744
$3.54 P/Share
|
|
Jan 11
2022
|
Adrian Rawcliffe Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
14,362
-47.34%
|
$43,086
$3.56 P/Share
|
|
Jan 11
2022
|
Elliot Norry Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,770
-37.28%
|
$11,310
$3.56 P/Share
|
|
Jan 11
2022
|
John Lunger Chief Patient Supply Officer |
SELL
Open market or private sale
|
Direct |
3,770
-37.28%
|
$11,310
$3.56 P/Share
|
|
Jan 11
2022
|
William C Bertrand Jr Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,770
-37.28%
|
$11,310
$3.56 P/Share
|
|
Jan 04
2022
|
Adrian Rawcliffe Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,532
-47.27%
|
$22,128
$4.06 P/Share
|
|
Jan 04
2022
|
Elliot Norry Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
849
-37.95%
|
$3,396
$4.06 P/Share
|
|
Jan 04
2022
|
John Lunger Chief Patient Supply Officer |
SELL
Open market or private sale
|
Direct |
1,070
-37.88%
|
$4,280
$4.06 P/Share
|
|
Jan 04
2022
|
William C Bertrand Jr Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,490
-37.27%
|
$13,960
$4.06 P/Share
|
|
Sep 01
2021
|
Adrian Rawcliffe Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,782
-47.54%
|
$13,910
$5.2 P/Share
|
|
Aug 02
2021
|
John Lunger Chief Patient Supply Officer |
SELL
Open market or private sale
|
Direct |
2,939
-37.62%
|
$8,817
$3.58 P/Share
|
|
Jul 02
2021
|
John Lunger Chief Patient Supply Officer |
SELL
Open market or private sale
|
Direct |
1,907
-37.56%
|
$7,628
$4.26 P/Share
|
|
Jul 02
2021
|
William C Bertrand Jr Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
4,375
-37.38%
|
$17,500
$4.26 P/Share
|
|
Jun 28
2021
|
Adrian Rawcliffe Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,794
-47.74%
|
$11,176
$4.37 P/Share
|
|
Jun 01
2021
|
Lawrence M Alleva Director |
BUY
Open market or private purchase
|
Indirect |
12,600
+50.0%
|
$0
$0.79 P/Share
|
|
Mar 03
2021
|
Helen Katrina Tayton Martin Chief Business & Strgy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,785,000
+49.79%
|
$0
$0.16 P/Share
|
|
Jan 19
2021
|
Adrian Rawcliffe Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
9,879
-42.2%
|
$49,395
$5.67 P/Share
|
|
Jan 19
2021
|
John Lunger Chief Patient Supply Officer |
SELL
Open market or private sale
|
Direct |
4,358
-37.24%
|
$21,790
$5.67 P/Share
|
|
Jan 19
2021
|
Elliot Norry Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,111
-37.36%
|
$10,555
$5.67 P/Share
|
|
Jan 12
2021
|
Adrian Rawcliffe Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,707
-42.28%
|
$16,242
$6.15 P/Share
|
|
Jan 12
2021
|
Elliot Norry Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
841
-37.6%
|
$5,046
$6.15 P/Share
|
|
Jan 12
2021
|
John Lunger Chief Patient Supply Officer |
SELL
Open market or private sale
|
Direct |
1,058
-37.45%
|
$6,348
$6.15 P/Share
|
|
Jan 12
2021
|
William C Bertrand Jr Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,234
-37.22%
|
$13,404
$6.15 P/Share
|
|
Jan 04
2021
|
Adrian Rawcliffe Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,967
-42.44%
|
$24,835
$5.33 P/Share
|
|
Jan 04
2021
|
Elliot Norry Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
845
-37.77%
|
$4,225
$5.33 P/Share
|
|
Jan 04
2021
|
William C Bertrand Jr Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,499
-37.37%
|
$17,495
$5.33 P/Share
|
|
Jan 04
2021
|
John Lunger Chief Patient Supply Officer |
SELL
Open market or private sale
|
Direct |
1,065
-37.7%
|
$5,325
$5.33 P/Share
|
|
Dec 14
2020
|
Gavin Wood Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
24,000
+29.63%
|
$0
$0.69 P/Share
|
|
Dec 14
2020
|
William C Bertrand Jr Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
207,000
+42.09%
|
$0
$0.69 P/Share
|
|
Jun 06
2018
|
Orbimed Advisors LLC Director |
SELL
Open market or private sale
|
Indirect |
1,600
-0.03%
|
$20,800
$13.49 P/Share
|
|
Jun 04
2018
|
Orbimed Advisors LLC Director |
SELL
Open market or private sale
|
Indirect |
17,100
-0.35%
|
$222,300
$13.57 P/Share
|
|
Jun 01
2018
|
Orbimed Advisors LLC Director |
SELL
Open market or private sale
|
Indirect |
50,000
-1.01%
|
$650,000
$13.49 P/Share
|
|
May 30
2018
|
Orbimed Advisors LLC Director |
SELL
Open market or private sale
|
Indirect |
121,000
-2.38%
|
$1,573,000
$13.52 P/Share
|
|
May 14
2018
|
Orbimed Advisors LLC Director |
SELL
Open market or private sale
|
Indirect |
10,300
-0.2%
|
$133,900
$13.5 P/Share
|
|
Mar 29
2018
|
Orbimed Advisors LLC Director |
SELL
Open market or private sale
|
Indirect |
31,983
-0.62%
|
$351,813
$11.53 P/Share
|
|
Mar 27
2018
|
Orbimed Advisors LLC Director |
SELL
Open market or private sale
|
Indirect |
1,016,084
-16.52%
|
$11,176,924
$11.5 P/Share
|